Jim Mason

Cancer Genetics and Epigenetics, MedSci Publisher, Richmond, BC, V7A 4Z5, Canada
Author    Correspondence author
Cancer Genetics and Epigenetics, 2024, Vol. 12, No. 1   doi: 10.5376/cge.2024.12.0008
Received: 03 Feb., 2024    Accepted: 18 Feb., 2024    Published: 25 Feb., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mason J., 2024, Multiplex immunofluorescence in colorectal cancer: A retrospective analysis from SCOT and QUASAR 2 Trials, Cancer Genetics and Epigenetics, 12(1): 66-69 (doi: 10.5376/cge.2024.12.0008)

"The Lancet Oncology" published an article on February 1, 2024, titled "Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis." The authors, Anja L. Frei, Anthony McGuigan, Ritik R.A.K Sinha, David N. Church, Viktor H. Koelzer, among others, are affiliated with the University of Zurich, Wellcome Centre for Human Genetics at the Nuffield Department of Medicine, University of Oxford, and the Cancer Research UK Glasgow Clinical Trials Unit at the University of Glasgow and other units. David N. Church is the corresponding author. This research utilizes data from the SCOT and QUASAR 2 clinical trials to deeply analyze the prognostic significance of intratumoural immune cell infiltrates in stage II-III colorectal cancer. Employing advanced multiplex immunofluorescence staining techniques, the study evaluates the density of various immune cells including CD8+cytotoxic T cells, FoxP3+regulatory T cells, CD20+B cells, and CD68+macrophages within the tumor microenvironment. The primary goal of the research is to reveal the associations between these immune cells and the patients' recurrence-free interval and overall prognosis. This method aims to optimize risk stratification in colorectal cancer and provide guidance for personalized treatment strategies.

Colorectal cancer; SCOT; QUASAR